Learn through insight

The serial acquisition thresholds will be relevant to businesses pursuing growth through an inorganic aggregation strategy , although some of the points in this article will also be relevant to the broader regime.

When ASIC released its Capital Markets Roadmap (REP 823) in November, it foreshadowed the introduction of an “easily-referenced regulatory guidance catalogue” for funds management. That commitment has now materialised: ASIC’s Regulatory Catalogue for Private Credit and Funds Management consolidates, in a single resource, the core legislative provisions, regulatory guides, information sheets and class orders that apply across the life-cycle of a fund.

In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions (PTE): Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161. The decision overturns years of case law and Patent Office practice, and means that many granted patents are likely now vulnerable to having their patent terms slashed. This article discusses how the law has changed, and what this means for developers and users of patented pharmaceutical technology in Australia.